Funding Agency: National Institutes of Health Title: Integration of Novel Measures for Improved Classification of Type 2 Diabetes Biostatistics Research Center (U01 Clinical Trial Not Allowed) Application Deadline: October 26, 2023 This NOFO invites applications for a Biostatistics Research Center to participate in a consortium aimed at improving understanding of heterogeneity of type 2 diabetes (T2D). A separate NOFO (RFA-DK-23-019) will bring together investigative teams for integration of multiple data types, including markers of organ or tissue function, into analysis approaches for stratifying individuals T2D and developing more precise definitions of disease. The ultimate goal of this effort will be to 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding of the physiologic drivers of T2D subtypes to guide development of more effective precision interventions. Funding Agency: National Institutes of Health Title: Integration of Novel Measures for Improved Classification of Type 2 Diabetes (U01, Clinical Trials Not Allowed) Application Deadline: October 26, 2023 The purpose of this NOFO is to create a consortium to bring together investigative teams for integration of multiple data types, including markers of organ or tissue function, into analysis approaches for stratifying individuals with type 2 diabetes (T2D) and developing more precise definitions of disease. The ultimate goal of this effort will be to 1) develop a broadly applicable framework for identifying subtypes of T2D; and 2) increase understanding of the physiologic drivers of T2D subtypes to guide development of more effective precision interventions. Funding Agency: National Institutes of Health Title: Safety Evaluation and Toxicology Studies and Related Services for Drug Development Application Deadline: July 10, 2023 The objective is to conduct toxicology studies to support the preclinical development of therapeutics and diagnostics including the submission of regulatory filings. Contractors will be required to perform in vitro and in vivo safety studies for small and large molecules to support the submission of regulatory filings to the US Food and Drug Administration (FDA) or other regulatory bodies, such as Investigational New Drug (IND) applications, New Drug Applications (NDA) and Biologics License Applications (BLA). In addition, in vitro tests and in vivo exploratory studies will be carried out to aid therapeutic target evaluation, lead optimization, and compound selection processes on a case-by-case basis. Therapeutic modalities may include new and repurposed chemical entities and biological products (e.g., monoclonal antibodies, enzymes, gene vectors, etc.). Funding Agency: National Institutes of Health Title: NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required) Application Deadline: Multiple deadlines For purposes of this Notice of Funding Opportunity (NOFO), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. Funding Agency: National Institutes of Health Title: NEI Collaborative Clinical Vision Research Project: Resource Center Grant (UG1 Clinical Trial Required) Application Deadline: Multiple deadlines The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Notice of Funding Opportunity (NOFO), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this NOFO encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high-risk clinical trial. Funding Agency: National Institutes of Health Title: Broadening Opportunities for Computational Genomics and Data Science Education (UE5 – Clinical Trial Not Allowed) Anticipated Application Deadline: October 10, 2023 The goal of the intended NOFO is to support faculty members at institutions with a mission to serve historically underrepresented populations in biomedical research to develop undergraduate and master’s degree-level educational content in computational genomics, data science, or a combination of these topics. Content developed will be expected to leverage the resources of NIH cloud computing platforms such as NHGRI’s AnVIL and the All of Us Researcher Workbench. Funding Agency: Centers for Disease Control and Prevention Title: Research Grants for Preventing Violence and Violence Related Injury (R01) Anticipated Application Deadline: December 01, 2023 The Centers for Disease Control and Prevention's National Center for Injury Prevention and Control (NCIPC) is soliciting investigator-initiated research that will help expand and advance understanding of approaches to prevent community violence and eliminate racial and ethnic inequities in risk for community violence. This initiative is intended to support effectiveness research to evaluate innovative programs, practices, or policies to address risk for violence and inequities in risk for violence among groups experiencing a high burden of community violence. Innovative approaches are those that have not been rigorously evaluated for effectiveness in reducing community violence. Consistent with CDC’s commitment to achieving health equity, investigation of inequities in exposure to and uptake of the selected approaches, and/or stratified analyses examining the differential impacts of the approach across populations disproportionately impacted by violence is a priority. Funds are available to conduct studies focused on preventing all forms of community violence involving youth or young adults (ages 10-34 years), including assaults, homicides, violence between groups, and threats/use of weapons. The primary objectives we wish to achieve with this initiative are: Objective One: Effectiveness research to evaluate innovative approaches with the potential for immediate or near immediate benefits (i.e., within 6 months) for reducing community violence and racial/ethnic inequities in risk for community violence. Objective Two: Effectiveness research to evaluate innovative place-based prevention approaches for reducing community violence and racial/ethnic inequities in risk for community violence. Objective Three: Effectiveness research to evaluate approaches that improve the social or structural conditions that contribute to community violence and racial/ethnic inequities in risk for community violence. Applicants are asked to clearly indicate in the application’s Abstract which objective, or combination of objectives, the research proposal intends to address. Funding Agency: Centers for Disease Control and Prevention Title: Grants to Support New Investigators in Conducting Research Related to Preventing Interpersonal Violence Impacting Children and Youth Anticipated Application Deadline: December 01, 2023 The purpose of the Centers for Disease Control and Prevention National Center for Injury Prevention and Control (NCIPC) Mentored Research Scientist Development Award (K01) is to provide support for an intensive, supervised (mentored) career development experience in violence prevention research leading to research independence. NCIPC supports K01 grants to help ensure the availability of an adequate number of trained scientists to address critical public health research questions to prevent violence and injury. Applicants must propose a research project that addresses at least one of the research priorities in the interpersonal violence prevention section of the NCIPC Research Priorities (www.cdc.gov/injury/researchpriorities/index.html) as they relate to violence impacting children or youth (from birth through age 17). Funding Agency: Centers for Disease Control and Prevention Title: Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) Anticipated Application Deadline: April 26, 2024 The Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) Notice of Funding Opportunity (NOFO) builds upon the program that was initiated in 1995 as one of the key activities under CDC’s plan to address emerging infectious disease threats. The purpose of this NOFO is to protect the public health and safety of the American people by enhancing the capacity of public health agencies to effectively detect, respond, prevent and control known an emerging (or re-emerging) infectious diseases. This is accomplished by providing financial and technical resources to (1) strengthen epidemiologic capacity; (2) enhance laboratory capacity; (3) improve information systems; and (4) enhance collaboration among epidemiology, laboratory, and information systems components of public health departments.
|